{
  "abstract": "Mesenchymal stem cells (MSCs) are promising platforms for regenerative and immunomodulatory therapies, but their clinical performance is limited by donor heterogeneity, variable potency, and limited persistence. CRISPR-based engineering provides programmable approaches to modify MSC function through genome editing and transcriptional regulation. This review examines CRISPR/Cas9-mediated knockout and knock-in, dCas9-based transcriptional regulation, and emerging base-, prime-, and epigenome-editing technologies for MSC engineering. These approaches can enhance survival and stress resistance, homing and tissue retention, paracrine and extracellular vesicle activity, immunomodulation, immune compatibility, and lineage-associated functions. Key translational challenges include efficient delivery, engineered-population heterogeneity, genomic safety, immunogenicity, phenotypic stability, scalable manufacturing, and mechanism-linked potency assessment. The appropriate engineering strategy should therefore be selected according to the intended therapeutic mechanism and product development requirements. Clinical translation will ultimately depend on demonstrating reproducible functional enhancement, manufacturing consistency, genomic and phenotypic stability, and validated therapeutic potency.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor 45363, Indonesia",
    "Prodia StemCell Indonesia, DKI Jakarta, Jakarta 13410, Indonesia"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Geofanny Facicilia"
    },
    {
      "affs": [
        1
      ],
      "name": "Cynthia Retna Sartika"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuni Elsa Hadisaputri",
      "orcid": "0000-0002-8087-9152"
    },
    {
      "affs": [
        0
      ],
      "name": "Tina Rostinawati"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/99ns7dpz78gy6.bib",
  "cited_by": 0,
  "doi": "10.3390/cells15212029",
  "fulltext_url": null,
  "id": "99ns7dpz78gy6",
  "issns": [
    "2073-4409"
  ],
  "landing_url": "https://www.mdpi.com/2073-4409/15/21/2029",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-06",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/99ns7dpz78gy6.ris",
  "sources": [
    {
      "first_seen": "2026-11-10T00:21:28Z",
      "native_id": "10.3390/cells15212029",
      "source": "crossref",
      "url": "https://www.mdpi.com/2073-4409/15/21/2029"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "issn:2073-4409",
      "subfield": "cell-biology"
    }
  ],
  "title": "CRISPR-Based Engineering of Mesenchymal Stem Cells: Functional Enhancement, Translational Challenges, and Clinical Perspectives",
  "title_text": "CRISPR-Based Engineering of Mesenchymal Stem Cells: Functional Enhancement, Translational Challenges, and Clinical Perspectives",
  "type": "peer-reviewed",
  "updated_at": "2026-11-10T00:21:28Z",
  "url": "https://research.draconitic.com/paper/99ns7dpz78gy6",
  "venue": "Cells",
  "versions": []
}